Novel oral liquid formulation of SER-428 is designed for patients who cannot take oral capsules, including critically ill patients receiving nutrition via feeding tube

SER-428 significantly reduced gastrointestinal abundance of clinically relevant pathogens in preclinical in vivo colonization models

CAMBRIDGE, Mass., Oct. 15, 2026 (GLOBE NEWSWIRE) -- Seres Therapeutics, Inc. (NASDAQ:MCRB), a leading live biotherapeutics company, today announced that preclinical data supporting the development of SER-428, an investigational oral liquid live biotherapeutic product (LBP) designed to reduce the risk of bloodstream infections (BSIs) in medically vulnerable patients following sepsis and antibiotic exposure, will be presented at IDWeek 2026, taking place October 21–24 in Washington, D.C.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.